{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:05:49Z","timestamp":1790024749904,"version":"4.0.1"},"reference-count":23,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,2,20]]},"abstract":"<jats:p>In the prevention and treatment of thromboembolic disease, novel oral anticoagulants have emerged as alternatives to warfarin. A major challenge continues to be the reversal of their anticoagulant effect in the case of life-threatening haemorrhagic complications. We report a case of spontaneous splenic rupture treated by splenic artery embolisation in a 77-year-old woman who was anticoagulated with rivaroxaban.<\/jats:p>","DOI":"10.1136\/bcr-2017-223237","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T14:15:28Z","timestamp":1520259328000},"page":"bcr-2017-223237","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Spontaneous splenic rupture due to rivaroxaban"],"prefix":"10.1136","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6579-6244","authenticated-orcid":false,"given":"Vinayak","family":"Nagaraja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Cranney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virag","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-21"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2007.01579.x"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.5","doi-asserted-by":"crossref","first-page":"950.e3","DOI":"10.1016\/j.ajem.2014.01.049","article-title":"Spontaneus splenic rupture in a patient treated with rivaroxaban","volume":"32","author":"Gonzva","year":"2014","journal-title":"Am J Emerg Med"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.6","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1177\/000313481608200208","article-title":"Hemorrhagic Shock from Spontaneous Splenic Rupture Requiring Open Splenectomy in a Patient Taking Rivaroxaban","volume":"82","author":"Amin","year":"2016","journal-title":"Am Surg"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.7","unstructured":"Yousef AH , Daniel S , Omar B . Rivaroxaban Causing Spontanuos Splenic Rupture, in C52. Illustrative disease presentations in critical care I: American Thoracic Society, 2015:A4632."},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5455\/ijsm.spleenrupture","article-title":"Spontaneous splenic rupture secondary to rivaroxaban: Rare but raising","volume":"2","author":"Naseem","year":"2016","journal-title":"IJSM"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-016-1012-6","article-title":"Spontaneous splenic rupture associated with apixaban: a case report","volume":"10","author":"Lowry","year":"2016","journal-title":"J Med Case Rep"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.10","doi-asserted-by":"crossref","first-page":"2082.e1","DOI":"10.1016\/j.ajem.2011.10.031","article-title":"Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation","volume":"30","author":"Moore","year":"2012","journal-title":"Am J Emerg Med"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.11","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013504741"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ijcard.2016.08.310","article-title":"A new scoring system (DAIGA) for predicting bleeding complications in atrial fibrillation patients after drug-eluting stent implantation with triple antithrombotic therapy","volume":"223","author":"Kobayashi","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.14","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv030"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.15","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-13-239","article-title":"Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial","volume":"13","author":"Carcas","year":"2012","journal-title":"Trials"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2174\/1574886310666150416123530","article-title":"New Oral Anticoagulants and Their Reversal","volume":"10","author":"Pinto","year":"2015","journal-title":"Curr Drug Saf"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502000"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for Dabigatran Reversal - Full Cohort Analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3102"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMe1610510","article-title":"Engineering Reversal - Finding an Antidote for Direct Oral Anticoagulants","volume":"375","author":"Hunt","year":"2016","journal-title":"N Engl J Med"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.21","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510991"},{"key":"2025042702594536000_2018.mar05_1.bcr-2017-223237.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1411800"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-223237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T09:59:57Z","timestamp":1745747997000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-223237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":23,"alternative-id":["10.1136\/bcr-2017-223237"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-223237","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]}}}